3-N-hydrocinnammoylamino-3-deoxy-1,2:3,4-di-O-isopropylidene-α-D-allofuranose | 1118980-04-3

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 3-N-hydrocinnammoylamino-3-deoxy-1,2:3,4-di-O-isopropylidene-α-D-allofuranose
• 英文别名: 3-N-hydrocinnammoyl-3-deoxy-1,2:3,4-di-O-isopropylidene-α-D-allofuranose；1,2;5,6-di-O-isopropylidene-3-deoxy-3-(3-phenyl-propionamido)-α-D-allofuranoside；1,2;5,6-di-O-isopropylidene-3-deoxy-3-(phenylpropionamido)-α-D-allofuranoside；N-[(3aR,5S,6R,6aR)-5-[(4R)-2,2-dimethyl-1,3-dioxolan-4-yl]-2,2-dimethyl-3a,5,6,6a-tetrahydrofuro[2,3-d][1,3]dioxol-6-yl]-3-phenylpropanamide
• CAS: 1118980-04-3
• 化学式: C₂₁H₂₉NO₆
• 分子量: 391.464
• InChiKey: XYVHFSCJQGGGHE-WSIUPNEHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  28
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  75.2
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  1,2:5,6-二-o-异亚丙基-alpha-d-ribo-3-己呋喃核糖 在 N-甲基吗啉 、 吡啶 、 lithium aluminium tetrahydride 、 盐酸羟胺 作用下， 以 四氢呋喃 、 乙醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 46.67h， 生成 3-N-hydrocinnammoylamino-3-deoxy-1,2:3,4-di-O-isopropylidene-α-D-allofuranose
  参考文献：
  名称：

  Monosaccharide derivatives as anti-inflammatory agents

  摘要：

  本发明涉及单糖衍生物作为抗炎药剂。本文披露的化合物可用于抑制和预防炎症及相关病理，包括炎症性、癌症、心血管和自身免疫疾病，如支气管哮喘、类风湿关节炎、I型糖尿病、多发性硬化症、移植排斥、牛皮癣、炎症性肠病、溃疡性结肠炎、痤疮、动脉粥样硬化、瘙痒或过敏性鼻炎。还提供了含有本文披露的化合物的药理组合物和治疗支气管哮喘、类风湿关节炎、I型糖尿病、多发性硬化症、癌症、心血管疾病、移植排斥、牛皮癣、炎症性肠病、溃疡性结肠炎、痤疮、动脉粥样硬化、瘙痒或过敏性鼻炎等疾病的方法，以及使用这些化合物治疗其他炎症性和/或自身免疫性疾病的方法。

  公开号：

  EP1953170A1

文献信息

• MONOSACCHARIDE DERIVATIVES
  申请人：Verma Ashwani Kumar

  公开号：US20080300196A1

  公开（公告）日：2008-12-04

  The present invention relates to monosaccharide derivatives as anti-inflammatory agents. The compounds disclosed herein can be useful for inhibition and prevention of inflammation and associated pathologies including inflammatory, cancer, cardiovascular and autoimmune diseases such as bronchial asthma, rheumatoid arthritis, type-I diabetes, multiple sclerosis, allograft rejection, psoriasis, inflammatory bowel disease, ulcerative colitis, acne, atherosclerosis, pruritis or allergic rhinitis. Pharmacological compositions containing compounds disclosed herein and the methods of treating diseases such as bronchial asthma, rheumatoid arthritis, type-I diabetes, multiple sclerosis, cancer, cardiovascular diseases, allograft rejection, psoriasis, inflammatory bowel disease, ulcerative colitis, acne, atherosclerosis, pruritis or allergic rhinitis and other inflammatory and/or autoimmune disorders, using the compounds are also provided.

  本发明涉及单糖衍生物作为抗炎药物。本文披露的化合物可用于抑制和预防炎症及相关病理，包括炎症性、癌症、心血管和自身免疫疾病，如支气管哮喘、类风湿关节炎、I型糖尿病、多发性硬化症、移植排斥、牛皮癣、炎症性肠病、溃疡性结肠炎、痤疮、动脉粥样硬化、瘙痒或过敏性鼻炎。还提供了含有本文披露的化合物的药理组合物和治疗支气管哮喘、类风湿关节炎、I型糖尿病、多发性硬化症、癌症、心血管疾病、移植排斥、牛皮癣、炎症性肠病、溃疡性结肠炎、痤疮、动脉粥样硬化、瘙痒或过敏性鼻炎等疾病的方法，以及使用这些化合物治疗其他炎症和/或自身免疫性疾病的方法。
• Synthesis of glycose carbamides and evaluation of the induction of erythroid differentiation of human erythroleukemic K562 cells
  作者：Martina Landi、Giorgio Catelani、Felicia D'Andrea、Eleonora Ghidini、Gabriele Amari、Puccini Paola、Nicoletta Bianchi、Roberto Gambari

  DOI：10.1016/j.ejmech.2008.05.001

  日期：2009.2

  A series of carbamides derived from 1,2:5,6-di-O-isopropylidene-D-gluco- (1) and D-allofuranose (3) as well as their 5,6-O-deprotected analogues (2 and 4) and methyl 3,4-O-isopropylidene-alpha- and beta-D-galactopyranosides (5 and 6) have been prepared in order to evaluate their ability to induce erythroid differentiation of human erythroleukemic K562 cells. Twenty out of 51 carbamides tested exhibit an appreciable activity as inducers of erythroid differentiation and have been fully characterized and described. (c) 2008 Elsevier Masson SAS. All rights reserved.
• Monosaccharide derivatives as anti-inflammatory agents
  申请人：Ranbaxy Laboratories Limited

  公开号：EP1953170A1

  公开（公告）日：2008-08-06

  The present invention relates to monosaccharide derivatives as anti-inflammatory agents. The compounds disclosed herein can be useful for inhibition and prevention of inflammation and associated pathologies including inflammatory, cancer, cardiovascular and autoimmune diseases such as bronchial asthma, rheumatoid arthritis, type-I diabetes, multiple sclerosis, allograft rejection, psoriasis, inflammatory bowel disease, ulcerative colitis, acne, atherosclerosis, pruritis or allergic rhinitis. Pharmacological compositions containing compounds disclosed herein and the methods of treating diseases such as bronchial asthma, rheumatoid arthritis, type-I diabetes, multiple sclerosis, cancer, cardiovascular diseases, allograft rejection, psoriasis, inflammatory bowel disease, ulcerative colitis, acne, atherosclerosis, pruritis or allergic rhinitis and other inflammatory and/or autoimmune disorders, using the compounds are also provided.

  本发明涉及单糖衍生物作为抗炎药剂。本文披露的化合物可用于抑制和预防炎症及相关病理，包括炎症性、癌症、心血管和自身免疫疾病，如支气管哮喘、类风湿关节炎、I型糖尿病、多发性硬化症、移植排斥、牛皮癣、炎症性肠病、溃疡性结肠炎、痤疮、动脉粥样硬化、瘙痒或过敏性鼻炎。还提供了含有本文披露的化合物的药理组合物和治疗支气管哮喘、类风湿关节炎、I型糖尿病、多发性硬化症、癌症、心血管疾病、移植排斥、牛皮癣、炎症性肠病、溃疡性结肠炎、痤疮、动脉粥样硬化、瘙痒或过敏性鼻炎等疾病的方法，以及使用这些化合物治疗其他炎症性和/或自身免疫性疾病的方法。